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Abstract 
Over the last decades, an increase in antipsychotic (AP) prescribing and a shift from first‑generation antipsychotics 
(FGA) to second‑generation antipsychotics (SGA) among youth have been reported. However, most AP prescrip‑
tions for youth are off‑label, and there are worrying long‑term safety data in youth. The objective of this study was 
to assess multinational trends in AP use among children and adolescents. A repeated cross‑sectional design was 
applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the 
United States (US) for calendar years 2005/2006–2012. The annual prevalence of AP use was assessed, stratified by age 
group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands’ data, 
from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK 
cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for 
SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. 
With the exception of the Netherlands, AP use prevalence was highest in 15–19 year‑olds. So, from 2005/6 to 2012, 
AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were 
favoured in all countries’ cohorts.
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Introduction
During the past decades, antipsychotic drugs (AP) have 
gained popularity as a treatment for psychiatric disorders 
in young people in most developed countries [1]. AP can 
be divided in two groups: first generation (typical) antip-
sychotics (FGA) and second-generation (atypical) antip-
sychotics (SGA) [2, 3]. Efficacy of AP in youth has been 
demonstrated for psychotic symptoms [4], bipolar dis-
order [5], irritability in autistic children [6], tics [7], and 
some forms of (severe) aggressive behaviour [8, 9]. Ample 
use of AP drugs has been described in children with a 
mental handicap and behavioral symptoms [10]. But only 
few antipsychotic drugs are licensed for those indications 
and for children and there is a lack of long-term efficacy 
and safety data [11]. Therefore, the treatment of youth 
with antipsychotics is subject to debate among clinicians, 
scientists and health policy makers [12].
Numerous reports from Western countries have 
described an increase in AP use, especially SGA, over 
recent years [1, 13–17]. These studies differ in terms of 
studied time period, age groups and other methodologi-
cal features, thus hampering comparability. While there 
are some multinational studies comparing antidepressant 
or ADHD medication use in children and adolescents 
[18–20], updating patterns of AP use across countries 
and regions is warranted.
The objective of this study is therefore to determine 
recent trends in AP use from 2005/2006 through 2012 in 
0- to 19 year-olds from five Western countries.
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Methods
Data sources
Denmark
We employed data from the Danish Registry of Medici-
nal Products Statistics (RMPS). The RMPS is a national 
prescription database, which encompasses all outpatient 
pharmacy-dispensed prescription medications in Den-
mark (5.53 million inhabitants). Each prescription record 
contains detailed information on the drug dispensed 
(incl. ATC code). Any drug utilisation prevalence can be 
calculated using an estimation of the underlying popula-
tion as denominator.
Germany
To perform this study, claims data of the single largest 
German health insurance company, the BARMER GEK 
(about 9.1 million insurees, representing more than 10% 
of the German population) was used. Each prescription 
record contains detailed information on the prescribed 
drug, including ATC code. In relation to the complete 
German population, the BARMER GEK has a slightly 
higher proportion of female insurees, but there are no 
differences in terms of socioeconomic status (as meas-
ured by education level) [21]. The German data of this 
study have been published before in a German publica-
tion [16].
The Netherlands
The data used for this study are pharmacy dispens-
ing data extracted from the IADB.nl database [22]. The 
IADB.nl database contains all prescription drug dispens-
ing data since 1994 from about 60 community pharma-
cies. The corresponding population consists of about 
600,000 persons from the North East Netherlands. In 
the Netherlands, patients are generally registered at one 
pharmacy, and there is an exchange of dispensing data 
between pharmacies. As a result, a single pharmacy can 
provide a complete listing of each registered subject’s 
prescribed drugs history, with the exception of over-the-
counter drugs and in-hospital prescriptions. The IADB.
nl database population is representative for the whole 
Dutch population [22].
United Kingdom
We used primary care prescribing data from The Health 
Improvement Network (THIN) primary care database. 
In the UK National Health Service, primary care doc-
tors (GP’s) are the gatekeepers of referral to both sec-
ondary and tertiary care. Children, including those with 
severe forms of mental disorders, are either not referred 
for assessment to specialist services or followed up in 
primary care. THIN holds information on prescriptions 
issued in general practices (GPs) in all four UK nations. 
The database covers approximately 6% of the UK popula-
tion and is broadly representative of the UK population 
in terms of demographics and consultation behaviour 
[23]. In this study, we only included practices that had 
achieved good quality data recording in terms of patient 
mortality, and average number of records per patient per 
year [24, 25]. In total, we included 552 practices that con-
tributed data between 2005 and 2012. Overall, prescrip-
tions recorded in THIN reflect redeemed prescriptions, 
with an average redemption rate of 98.5% in 2008. How-
ever, the redemption rate is slightly lower for AP pre-
scriptions at 85.1% in 2008 [26].
United States
We used computerized Medicaid administrative claims 
for the calendar years 2006 through 2012 from a nar-
rowly-defined population of youth (0–19  years) in a 
mid-Atlantic state enrolled in Children’s Health Insur-
ance Program (CHIP). These children and adolescents 
are eligible for Medicaid coverage due to family income 
(upper limit: three times the federal poverty level [27]. 
The cohort consisted of over 131,000 youth in 2006 and 
of over 105,000 youth in 2012. Youth who were on Med-
icaid due to (1) disability; (2) foster care status or (3) fam-
ily income below poverty level were excluded. Thus the 
population was similar to privately-insured youth in the 
US in terms of general health status, age distribution, 
race and family composition, with moderately lower 
parental education, employment, and income [28]. Each 
individual was assigned an encrypted identification num-
ber, which was then used to link the enrollment data files 
to prescription drug claim files.
Study variables and statistical analysis
Antipsychotics were defined as: all substances desig-
nated as class N05A (except Lithium) by the Anatomical 
Therapeutic Chemical (ATC) Code [29]. Of all AP the fol-
lowing drugs were considered second generation antipsy-
chotics: Amisulpride, aripiprazole, asenapine, clozapine, 
iloperidone, lurasidone, olanzapine, paliperidone, quetia-
pine, risperidone, sertindole, sulpiride, ziprasidone and 
zotepine. The remaining antipsychotic drugs were con-
sidered first generation (e.g. chlorprotixene, chlorproma-
zine, haloperidol and pipamperone).
Annual AP use prevalence was defined as the percent-
age of youth (0–19 years at the time of prescription) with 
one or more AP dispensings or prescriptions among 
continuously enrolled youths in a given calendar year 
in the 2005/6–2012 period. Rates were not adjusted for 
age - or sex composition across the cohorts. Relative dif-
ferences between years were calculated as the difference 
in prevalence, divided by the prevalence in the first year. 
The data were stratified by age groups (0–4, 5–9, 10–14, 
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15–19  years) and gender. The 95% confidence interval 
for the prevalence rates was calculated with the score 
method, with continuity correction for small proportions 
[30]. Differences were considered significant at p < .05.
Results
Trends in total use by country and according to age group
From 2005/6 to 2012 the annual prevalence for AP use 
for youth increased in four of the five countries under 
study (Fig. 1). This increase was as follows: in Denmark 
0.26 to 0.48% (83.9% relative increase), in the German 
cohort 0.23 to 0.32% (40.8% increase), in the Netherlands’ 
cohort (0.78 to 1.03% (31.7% increase), and in the UK 
cohort 0.11 to 0.14% (29.3% increase). A decrease from 
0.94 to 0.79% was observed in the US cohort (− 15.6%).
When comparing the prevalence of AP use between 
countries’ cohorts, large differences were observed 
(Table  1). In 2012, the highest AP use was observed in 
the Netherlands’ cohort (1360/131,954; 1.03%), which 
was eight-fold higher than in the country with the lowest 
prevalence (UK; 0.14%).
With the exception of the Netherlands’ cohort, AP use 
was higher in older age cohorts, with 15–19  year-olds 
showing the highest prevalence (2012: Denmark cohort 
1.33%, German cohort 0.54%, Netherlands’ cohort 1.47%, 
UK cohort 0.31%, US 2.53%). Only in the Netherlands’ 
cohort AP use prevalence was highest in 10–14  year 
olds (2012: 1.59%). For 0–4 year olds, after 2008 AP use 
remained lower than 1 per 1000 in all cohorts.
Trends in AP use by gender
In all studied cohorts, the prevalence of AP use was 
higher in boys than in girls (Table 2). In 2012, the male/
female ratio ranged from an almost threefold higher 
use by boys in the Netherlands’ data (2.87) to 1.38 in 
Denmark.
Across countries, AP use in girls was at or below 0.5% 
in contrast to AP use in boys that peaked at 1.54% in the 
Netherlands’ data and 1.05% in the US data. From 2005/6 
to 2012 use in boys increased relatively more than in girls 
in the German cohort, while the opposite was observed 
in the Netherlands’ and in the UK cohort. In the US data, 
use in boys decreased more than in girls (−  19.9% vs. 
− 5.3%). In Denmark, the increase in boys and girls was 
comparable.
Patterns in FGA use vs. SGA use by country
In all cohorts except the US cohort the proportion of 
SGA relative to FGA prescriptions increased (Fig. 2). In 
the US regional cohort, SGA were almost the only class 
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Fig. 1 Annual percent prevalence of antipsychotic drug use in children and adolescents (0–19 years) in cohorts from five countries, 2005/6–2012 
(with 95% confidence intervals)
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Table 1 Annual percent prevalence of  antipsychotic drug use in  cohorts from  five countries between  2005/6–2012 
among children and adolescents in 4 age group
2005 2006 2007 2008 2009 2010 2011 2012 Difference 
2005–2012
Denmark
 0–4 years 0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.00]
N/A
 5–9 years 0.07 
[0.06–0.08]
0.08 
[0.07–0.09]
0.09 
[0.08–0.10]
0.10 
[0.09–0.11]
0.12 
[0.11–0.13]
0.12 
[0.11–0.14]
0.11 
[0.10–0.13]
0.10 
[0.09–0.12]
44.9%
 10–14 years 0.26 
[0.24–0.28]
0.27 
[0.26–0.29]
0.33 
[0.31–0.35]
0.34 
[0.32–0.37]
0.39 
[0.36–0.41]
0.40 
[0.38–0.43]
0.40 
[0.38–0.42]
0.42 
[0.39–0.44]
61.5%
 15–19 years 0.77 
[0.73–0.80]
0.88 
[0.85–0.92]
0.94 
[0.90–0.97]
1.03 
[0.99–1.06]
1.11 
[1.08–1.15]
1.24 
[1.21–1.28]
1.30 
[1.26–1.34]
1.33 
[1.29–1.37]
74.3%
 Total 0.26 
[0.25–0.27]
0.30 
[0.29–0.31]
0.33 
[0.32–0.35]
0.37 
[0.36–0.38]
0.41 
[0.40–0.42]
0.46 
[0.44–0.47]
0.47 
[0.46–0.48]
0.48 
[0.47–0.50]
83.9%
Germany
 0–4 years 0.15 
[0.14–0.16]
0.04 
[0.03–0.05]
0.02 
[0.02–0.03]
0.02 
[0.02–0.03]
0.02 
[0.02–0.03]
0.02 
[0.01–0.02]
0.02 
[0.01–0.02]
0.01 
[0.01–0.02]
N/A
 5–9 years 0.13 
[0.12–0.15]
0.13 
[0.12–0.14]
0.15 
[0.14–0.17]
0.17 
[0.15–0.18]
0.18 
[0.16–0.19]
0.17 
[0.16–0.19]
0.17 
[0.16–0.18]
0.17 
[0.16–0.18]
25.7%
 10–14 years 0.24 
[0.23–0.26]
0.27 
[0.25–0.28]
0.31 
[0.29–0.33]
0.34 
[0.32–0.36]
0.37 
[0.35–0.39]
0.42 
[0.40–0.44]
0.42 
[0.41–0.45]
0.43 
[0.41–0.45]
76.8%
 15–19 years 0.34 
[0.33–0.36]
0.34 
[0.33–0.36]
0.37 
[0.35–0.39]
0.41 
[0.39–0.43]
0.44 
[0.42–0.46]
0.51 
[0.49–0.54]
0.51 
[0.52–0.56]
0.54 
[0.52–0.56]
57.4%
 Total 0.23 
[0.22–0.23]
0.21 
[0.20–0.22]
0.23 
[0.23–0.24]
0.26 
[0.25–0.26]
0.28 
[0.27–0.29]
0.31 
[0.30–0.32]
0.31 
[0.31–0.33]
0.32 
[0.31–0.33]
40.8%
Netherlands
 0–4 years 0.12 
[0.09–0.17]
0.08 
[0.06–0.12]
0.09 
[0.07–0.13]
0.09 
[0.07–0.13]
0.06 
[0.04–0.10]
0.09 
[0.06–0.13]
0.06 
[0.04–0.09]
0.07 
[0.05–0.11]
N/A
 5–9 years 0.80 
[0.71–0.91]
0.87 
[0.77–0.98]
1.01 
[0.91–1.12]
0.95 
[0.85–1.06]
0.97 
[0.87–1.08]
0.96 
[0.86–1.07]
0.86 
[0.77–0.97]
0.84 
[0.75–0.95]
5.3%
 10–14 years 1.18 
[1.06–1.30]
1.32 
[1.20–1.45]
1.56 
[1.43–1.70]
1.65 
[1.51–1.79]
1.68 
[1.55–1.83]
1.69 
[1.55–1.83]
1.67 
[1.53–1.81]
1.59 
[1.47–1.73]
35.5%
 15–19 years 1.04 
[0.94–1.16]
1.12 
[1.02–1.24]
1.15 
[1.04–1.26]
1.35 
[1.24–1.47]
1.44 
[1.33–1.57]
1.37 
[1.26–1.49]
1.34 
[1.23–1.47]
1.47 
[1.35–1.60]
40.8%
 Total 0.78 
[0.74–0.83]
0.84 
[0.80–0.89]
0.95 
[0.90–1.01]
1.02 
[0.97–1.07]
1.02 
[0.97–1.07]
1.04 
[0.99–1.10]
1.01 
[0.96–1.06]
1.03 
[0.98–1.09]
31.7%
UK
 0–4 years 0.00 
[0.00–0.01]
0.00 
[0.00–0.01]
0.00 
[0.00–0.00]
0.00 
[0.00–0.00]
0.00 
[0.00–0.00]
0.00 
[0.00–0.01]
0.00 
[0.00–0.00]
0.00 
[0.00–0.01]
N/A
 5–9 years 0.03 
[0.03–0.04]
0.03 
[0.03–0.04]
0.04 
[0.03–0.05]
0.04 
[0.03–0.05]
0.04 
[0.03–0.05]
0.05 
[0.04–0.06]
0.04 
[0.03–0.05]
0.03 
[0.02–0.04]
− 16.7%
 10–14 years 0.12 
[0.11–0.14]
0.13 
[0.12–0.15]
0.13 
[0.12–0.14]
0.14 
[0.12–0.15]
0.14 
[0.13–0.16]
0.14 
[0.13–0.16]
0.15 
[0.13–0.16]
0.16 
[0.14–0.17]
27.5%
 15–19 years 0.25 
[0.23–0.28]
0.27 
[0.25–0.29]
0.28 
[0.26–0.30]
0.26 
[0.24–0.28]
0.26 
[0.25–0.29]
0.31 
[0.29–0.33]
0.33 
[0.31–0.35]
0.31 
[0.28–0.33]
20.5%
 Total 0.11 
[0.10–0.11]
0.11 
[0.11–0.12]
0.12 
[0.11–0.12]
0.12 
[0.11–0.12]
0.12 
[0.11–0.13]
0.13 
[0.13–0.14]
0.14 
[0.13–0.15]
0.14 
[0.13–0.15]
29.3%
USA
 0–4 years N/A 0.16 
[0.13–0.19]
0.12 
[0.10–0.15]
0.10 
[0.08–0.13]
0.07 
[0.05–0.09]
0.05 
[0.03–0.07]
0.04 
[0.03–0.07]
0.02 
[0.01–0.04]
N/A
 5–9 years N/A 1.31 
[1.18–1.47]
1.39 
[1.25–1.54]
1.17 
[1.04–1.31]
1.04 
[0.92–1.18]
0.82 
[0.71–0.94]
0.69 
[0.59–0.81]
0.56 
[0.47–0.66]
− 57.5%
 10–14 years N/A 2.53 
[2.33–2.75]
2.59 
[2.39–2.82]
2.50 
[2.29–2.72]
2.50 
[2.29–2.73]
2.23 
[2.03–2.44]
2.31 
[2.11–2.53]
1.91 
[1.73–2.10]
− 24.6%
 15–19 years N/A 2.41 
[2.14–2.71]
2.75 
[2.47–3.06]
2.87 
[2.59–3.19]
3.07 
[2.77–3.41]
2.80 
[2.50–3.13]
2.69 
[2.41–3.01]
2.53 
[2.26–2.83]
5.0%
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of drugs used, both in 2006 (98.5% of all prescriptions) 
and in 2012 (98.3%). In 2005/6 and 2012, risperidone was 
the most frequently used AP in all countries’ cohorts, 
with the exception of Denmark, where in 2012 quetiapine 
ranked first. Use of aripiprazole, a relatively new drug 
that was approved by the FDA for irritability in autistic 
children in 2009, increased clearly: While in 2005/6 ari-
piprazole was only in Denmark and the US data among 
the top-5 prescribed AP, in 2012 it was in all countries 
among the five most frequently used AP (Table 3).
Discussion
We observed large differences between samples from 5 
countries in the prevalence of AP use, with AP use being 
highest in the US cohort and lowest in the UK cohort. 
Since 2007, AP use in the Netherlands’ cohort has sur-
passed use in the US cohort. Also time trends varied 
significantly: In the Netherlands’ data, AP use stabilized 
from 2008 to 2012. In the US cohort, the prevalence of 
AP use stabilized and decreased towards 2012. All other 
countries showed a trend for increased use. In most 
countries’ data, AP use was greatest in 15–19 year-olds. 
We observed a strong and in most countries increasing 
preference for SGA, relative to FGA.
There are several possible explanations for the differ-
ences in AP use in youth cohorts from different coun-
tries: The attitude of prescribers towards psychotropic 
drugs and antipsychotic drugs and differences in health 
systems can be a factor that influences AP prescription 
rates [31]. For example: the attitude of physicians that 
SGA should be used to treat aggressive behavior can 
contribute to higher AP prescription rates [32] and the 
acceptance of psychiatric medication for children by the 
general public may be a factor [33]. Several studies indi-
cate a broadening of indications, for example in ADHD 
and other disruptive behaviour disorders [13, 16, 34, 35].
Higher use of AP drugs can be associated with a 
stronger representation of medical disciplines in the care 
for youth with behavioral and psychiatric disorders or 
with an increasing use of mental health care [36]. Gaps 
in the mental health care system, e.g. lack of social care 
for the afore-mentioned patient group, may also lead to 
higher AP prescriptions [37]. It has been demonstrated 
that longer duration of treatment—and not only more 
new users—is a relevant factor in the increase in preva-
lence [14, 38, 39]. The decrease in use in the US confirms 
recent findings from the US [35] and could be influenced 
by measures to constrain AP use in youth. For example, 
recommendations for a more rigorous monitoring of 
side effects of AP, e.g.: [40, 41] have appeared. In the US, 
awareness programs targeting clinicians and the public 
were developed [42] and a system for prior authorization 
of antipsychotic prescribing for Medicaid insured youth 
[43] is implemented in 31 states.
We cannot fully explain the higher AP use in the Neth-
erlands (which parallels the Netherlands position in 
international ADHD medication use [20]) despite the fact 
that regulatory approval is harmonized across European 
countries. In the Netherlands, treatment with AP has 
been included in some guidance statements, but not as 
a first line treatment option [44]. This finding may reflect 
a period of emphasis on the biomedical model in Dutch 
Numbers in brackets = 95% confidence interval
For the USA, only data from 2006 to 2012 were available
Table 1 continued
2005 2006 2007 2008 2009 2010 2011 2012 Difference 
2005–2012
 Total N/A 0.94 
[0.89–0.99]
0.97 
[0.92–1.03]
0.93 
[0.88–0.98]
0.96 
[0.91–1.02]
0.88 
[0.82–0.94]
0.90 
[0.85–0.96]
0.79 
[0.74–0.85]
− 15.6%
Table 2 Percent prevalence of  antipsychotic drug use 
in  2005/6 and  2012 in  0–19  year-olds in  cohorts from  5 
countries, divided by gender
Numbers in brackets = 95% confidence interval
For the USA, only data from 2006 to 2012 were available
M male; F Female
a Based on 2006
2005 (USA:2006) M/F ratio 2012 M/F ratio
Denmark
 F 0.22 [0.21–0.23] 1.39 0.40 [0.39–0.42] 1.38
 M 0.31 [0.29–0.32] 0.56 [0.54–0.58]
Germany
 F 0.16 [0.15–0.17] 1.85 0.19 [0.18–0.20] 2.28
 M 0.29 [0.28–0.30] 0.44 [0.43–0.46]
Netherlands
 F 0.37 [0.33–0.42] 3.18 0.51 [0.46–0.57] 2.87
 M 1.19 [1.11–1.27] 1.54 [1.45–1.63]
United Kingdom
 F 0.07 [0.06–0.08] 2.15 0.09 [0.08–0.10] 1.88
 M 0.14 [0.13–0.16] 0.18 [0.17–0.19]
USA (2006)a
 F 0.55 [0.50–0.61] 2.39 0.52 [0.46–0.59] 1.95
 M 1.32 [1.24–1.40] 1.05 [0.97–1.14]
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Child and Adolescent Mental Health care. However, the 
strongest increase in the use of antipsychotics in youth 
predates the current period under study and unfolded 
in the period 1995–2005 [14]. It will be worthwhile to 
observe trends in the Netherlands from 2015 onwards, 
since important changes have been implemented since 
2015 in the position of Child and Adolescent Mental 
Health care [45], with as one of the objectives a reduction 
in the use of psychopharmacological drugs in children.
In contrast, the low prescription rates found in the 
UK cohort may be related to the nature of the UK data, 
covering only prescriptions issued in primary care. So 
prescriptions by specialists are not taken into account. 
Another reason may be that the NICE guideline for 
ADHD [46] advices against use of antipsychotics in 
ADHD and the NICE guideline for antisocial behavior 
and conduct disorders [47] advices against medication 
as routine management for children with this condi-
tion—which stands in contrast to some other countries’ 
guidelines.
The greatest AP use in 15–19  year-olds in 4 of the 5 
countries replicates findings by other authors where AP 
use increased towards early adolescence [13]. This is an 
age-group where behavioral problems tend to peak [48] 
and where severe mood disorders and psychotic disor-
ders emerge. Another factor may be reluctance in pre-
scribers towards prescribing for younger patients. The 
highest use in 10–14  year-olds that was found in the 
Netherlands may be explained by more use in behavioral 
disorders and by less reluctance towards prescribing in 
younger patients.
One explanation for the strong trend towards the use 
of SGA—which constitutes an exceptional growth in 
comparison to older studies (in 2000, in Germany only 
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Fig. 2 Second generation antipsychotic (SGA) use as a percentage of total antipsychotic use for children and adolescents in cohorts from five 
countries, 2005/6–2012
Table 3 The five most commonly used antipsychotic drugs for  children and  adolescents in  cohorts from  five countries, 
2005/6 vs 2012
For the USA, only data from 2006 to 2012 were available
ARI aripiprazole, CHP chlorprotixene, CPZ chlorpromazine, HAL haloperidol, OLA olanzapine, PIP pipamperone, PMZ promazine, QUE quetiapine, RIS risperidone, TIA 
tiapride, ZIP ziprasidone
Rank Denmark Germany Netherlands UK USA
2005 % 2012 % 2005 % 2012 % 2005 % 2012 % 2005 % 2012 % 2006¶ % 2012 %
1 RIS 31.9 QUE 24.1 RIS 30.6 RIS 49.6 RIS 57.8 RIS 51.7 RIS 58.2 RIS 53.8 RIS 57.1 RIS 53.1
2 CHP 24.0 RIS 22.0 PIP 20.4 PIP 16.5 PIP 21.4 QUE 14.4 OLA 14.3 ARI 14.1 ARI 30.2 ARI 31.4
3 OLA 9.8 CHP 21.9 TIA 11.9 QUE 9.5 QUE 6.2 PIP 11.7 HAL 5.4 QUE 14.1 QUE 17.9 QUE 16.9
4 QUE 9.1 ARI 19.0 PMZ 6.7 TIA 6.0 OLA 4.9 ARI 11.0 CPZ 5.3 OLA 11.7 OLA 8.1 ZIP 5.5
5 ARI 4.2 OLA 7.0 OLA 5.8 ARI 4.5 PMZ 3.4 OLA 6.0 QUE 3.9 HAL 1.8 ZIP 4.7 OLA 4.3
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5% of AP were SGA, [49])—may be that the literature 
about AP in youth is dominated by SGA focused papers, 
although the actual evidence base for efficacy is weak for 
most indications [50]. This may possibly an effect of more 
investment in the development and registration process 
of newer drugs. Previously, SGA were also considered 
more safe due to a smaller risk for extrapyramidal side 
effects [51] and tardive dyskinesia [52]. The insight that 
SGA are associated with different, but not necessarily 
smaller risks than FGA [53] is of more recent date since 
most reports about metabolic and endocrinological side 
effects have appeared in the last decade [40, 54–58].
Limitations, and implications of this study
This study is one of the first to describe use of antipsy-
chotics in youth cohorts from different countries. The 
diversity of the underlying databases is a limitation as 
the underlying populations differ and this will certainly 
influence the rates that we found: The Danish cohort 
is nationwide, the US cohort comprises CHIP insured 
patients from one state, the Netherlands cohort cov-
ers a region of the country, the German cohort com-
prises patients from one large insurance company, while 
the UK cohort covers prescriptions from primary care. 
So, between-country comparisons should be made with 
caution. We were not able to control for co-medication, 
prescribing physician specialty (GPs vs. specialists) or 
socio-economic status, factors which influence AP use 
[51, 59]. Our data sources lack information that could 
improve the perspective on AP use, such as underlying 
indication, ethnic background, foster care status, dura-
tion of pharmacotherapy, adherence, symptom severity 
and symptom duration. We did not consider medication 
for hospitalized children. But the number of hospitalized 
youth may be small, compared to outpatients [60], and 
usually medication is continued in the outpatient setting 
after discharge from hospital.
In this vein, future studies will benefit from the use of 
harmonized databases, information about diagnosis (e.g. 
[61]) and use of other treatments, concurrent or sequen-
tial, thus giving more insight on indications and unmet 
needs in care across populations [59]. Data about inci-
dence and duration of AP use is relevant, since longer 
exposure to the metabolic and endocrinological side 
effects of AP poses higher risks for health.
The implications of this study are that guidelines and 
practice parameters for AP use drugs need closer scru-
tiny. For those drugs where efficacy has been demon-
strated in RCTs of limited duration, there is a pressing 
need for longer lasting observational and discontinuation 
studies to determine the risks and benefits of long-term 
use  [62–64]. Close monitoring of use of psychophar-
macological agents over time and across countries may 
sensitize to national discrepancies in mental health care, 
differences in use of psychopharmacological treatment 
and populations with special needs or risks. For this 
purpose, a fixed multinational set of databases, gauged 
against each other, is an essential tool.
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